INS and type 2 diabetes mellitus: Exenatide was reported to normalize both first and second phases of glucose-induced insulin secretion in patients with type 2 diabetes during 3-hour intravenous infusion [10] and to provide long-term improvement of beta cell function by chronic treatment [11].